يعرض 1 - 10 نتائج من 16 نتيجة بحث عن '"melanoma/dt [Drug Therapy]"', وقت الاستعلام: 1.20s تنقيح النتائج
  1. 1
    مورد إلكتروني

    مصطلحات الفهرس: endometrium cancer/di [Diagnosis], endometrium cancer/dt [Drug Therapy], endometrium cancer/et [Etiology], enzyme inhibition, fatigue/si [Side Effect], female, fever/si [Side Effect], gastroesophageal reflux/si [Side Effect], glossodynia/si [Side Effect], hand foot syndrome/si [Side Effect], headache/si [Side Effect], human, hyperkeratosis/si [Side Effect], hypertension/si [Side Effect], hypomagnesemia/si [Side Effect], hypophosphatemia/si [Side Effect], hypotension/si [Side Effect], insomnia/si [Side Effect], intestine obstruction/si [Side Effect], intestine perforation/si [Side Effect], lethargy/si [Side Effect], limb pain/si [Side Effect], major clinical study, male, maximum plasma concentration, maximum tolerated dose, melanoma/di [Diagnosis], melanoma/dt [Drug Therapy], melanoma/et [Etiology], multiple cycle treatment, muscle spasm/si [Side Effect], musculoskeletal chest pain/si [Side Effect], myalgia/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non small cell lung cancer/di [Diagnosis], non small cell lung cancer/dt [Drug Therapy], non small cell lung cancer/et [Etiology], oncogene N ras, oropharynx pain/si [Side Effect], ovary cancer/di [Diagnosis], ovary cancer/dt [Drug Therapy], ovary cancer/et [Etiology], palmoplantar keratoderma/si [Side Effect], pericardial effusion/si [Side Effect], phase 1 clinical trial, photosensitivity/si [Side Effect], pleura effusion/si [Side Effect], positron emission tomography-computed tomography, priority journal, progression free survival, pruritus/si [Side Effect], QT prolongation/si [Side Effect], rash/si [Side Effect], sepsis/si [Side Effect], side effect/si [Side Effect], skin defect/si [Side Effect], skin hypertrophy/si [Side Effect], solid malignant neoplasm, thrombocytopenia/si [Side Effect], thrush/si [Side Effect], thyroid cancer/di [Diagnosis], thyroid cancer/dt [Drug Therapy], thyroid cancer/et [Etiology], thyroid papillary carcinoma/di [Diagnosis], thyroid papillary carcinoma/dt [Drug Therapy], thyroid papillary carcinoma/et [Etiology], treatment duration, upper abdominal pain/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], vomiting/si [Side Effect], xerostomia/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], B Raf kinase/ec [Endogenous Compound], K ras protein/ec [Endogenous Compound], lifirafenib/ae [Adverse Drug Reaction], lifirafenib/ct [Clinical Trial], lifirafenib/cr [Drug Concentration], lifirafenib/do [Drug Dose], lifirafenib/dt [Drug Therapy], lifirafenib/to [Drug Toxicity], lifirafenib/pd [Pharmacology], dizziness/si [Side Effect], abdominal pain/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], antineoplastic activity, arthralgia/si [Side Effect], article, backache/si [Side Effect], blood level, blood toxicity/si [Side Effect], body weight disorder/si [Side Effect], body weight loss, brain hemorrhage/si [Side Effect], cancer chemotherapy, cancer patient, cancer radiotherapy, cancer staging, cancer survival, chill/si [Side Effect], cohort analysis, colorectal cancer/di [Diagnosis], colorectal cancer/dt [Drug Therapy], colorectal cancer/et [Etiology], constipation/si [Side Effect], coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug blood level, drug dose increase, drug half life, drug safety, drug tolerability, dry skin/si [Side Effect], dysgeusia/si [Side Effect], dysphonia/si [Side Effect], dyspnea/si [Side Effect], Article

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28975
    Journal of Clinical Oncology
    Click here for full text options
    LibKey Link

  2. 2
    مورد إلكتروني

    مصطلحات الفهرس: hypercalcemia/si [Side Effect], hyperglycemia/si [Side Effect], hypertransaminasemia/si [Side Effect], hypokalemia/si [Side Effect], hyponatremia/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], loss of appetite/si [Side Effect], lower respiratory tract infection/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, maximum tolerated dose, melanoma/dt [Drug Therapy], merkel cell carcinoma/dt [Drug Therapy], microsatellite instability, monotherapy, multiple cycle treatment, nausea and vomiting/si [Side Effect], non small cell lung cancer/dt [Drug Therapy], optimal drug dose, ovary carcinoma/dt [Drug Therapy], pancreas cancer/dt [Drug Therapy], phase 1 clinical trial, pleura effusion/si [Side Effect], pneumonia/si [Side Effect], priority journal, rash/si [Side Effect], recommended drug dose, renal cell carcinoma/dt [Drug Therapy], retrospective study, sepsis/si [Side Effect], skin carcinoma/dt [Drug Therapy], small intestine obstruction/si [Side Effect], solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], time to maximum plasma concentration, treatment response time, triple negative breast cancer/dt [Drug Therapy], upper gastrointestinal bleeding/si [Side Effect], bilirubin/ec [Endogenous Compound], new drug/ct [Clinical Trial], new drug/do [Drug Dose], new drug/dt [Drug Therapy], new drug/to [Drug Toxicity], new drug/iv [Intravenous Drug Administration], new drug/pk [Pharmacokinetics], new drug/pv [Special Situation for Pharmacovigilance], programmed death 1 ligand 1/ec [Endogenous Compound], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/cr [Drug Concentration], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], tislelizumab/to [Drug Toxicity], tislelizumab/iv [Intravenous Drug Administration], tislelizumab/pk [Pharmacokinetics], tislelizumab/pv [Special Situation for Pharmacovigilance], tislelizumab/tm [Unexpected Outcome of Drug Treatment], immunohistochemical test kit, VENTANA PD-L1 (SP263), maximum concentration, adult, aged, anemia/si [Side Effect], antineoplastic activity, area under the curve, article, ascites/si [Side Effect], backache/si [Side Effect], bile duct carcinoma/dt [Drug Therapy], body weight disorder/si [Side Effect], clinical outcome, cohort analysis, colitis/si [Side Effect], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug dosage form comparison, drug dose escalation, drug dose regimen, drug efficacy, drug half life, drug safety, drug tolerability, drug withdrawal, dysphagia/si [Side Effect], dyspnea/si [Side Effect], esophagus cancer/dt [Drug Therapy], esophagus carcinoma/dt [Drug Therapy], fatigue/si [Side Effect], female, follow up, gastrointestinal stromal tumor/dt [Drug Therapy], head and neck squamous cell carcinoma/dt [Drug Therapy], human, hyperbilirubinemia/si [Side Effect], Article

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29145
    Journal for ImmunoTherapy of Cancer
    Click here for full text options
    LibKey Link

  3. 3
    مورد إلكتروني

    مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
    Australasian Journal of Dermatology
    Click here for full text options
    LibKey Link

  4. 4
  5. 5
    مورد إلكتروني

    مصطلحات الفهرس: hypercalcemia/si [Side Effect], hyperglycemia/si [Side Effect], hypertransaminasemia/si [Side Effect], hypokalemia/si [Side Effect], hyponatremia/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], loss of appetite/si [Side Effect], lower respiratory tract infection/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, maximum tolerated dose, melanoma/dt [Drug Therapy], merkel cell carcinoma/dt [Drug Therapy], microsatellite instability, monotherapy, multiple cycle treatment, nausea and vomiting/si [Side Effect], non small cell lung cancer/dt [Drug Therapy], optimal drug dose, ovary carcinoma/dt [Drug Therapy], pancreas cancer/dt [Drug Therapy], phase 1 clinical trial, pleura effusion/si [Side Effect], pneumonia/si [Side Effect], priority journal, rash/si [Side Effect], recommended drug dose, renal cell carcinoma/dt [Drug Therapy], retrospective study, sepsis/si [Side Effect], skin carcinoma/dt [Drug Therapy], small intestine obstruction/si [Side Effect], solid malignant neoplasm/dt [Drug Therapy], stomach cancer/dt [Drug Therapy], time to maximum plasma concentration, treatment response time, triple negative breast cancer/dt [Drug Therapy], upper gastrointestinal bleeding/si [Side Effect], bilirubin/ec [Endogenous Compound], new drug/ct [Clinical Trial], new drug/do [Drug Dose], new drug/dt [Drug Therapy], new drug/to [Drug Toxicity], new drug/iv [Intravenous Drug Administration], new drug/pk [Pharmacokinetics], new drug/pv [Special Situation for Pharmacovigilance], programmed death 1 ligand 1/ec [Endogenous Compound], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/cr [Drug Concentration], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], tislelizumab/to [Drug Toxicity], tislelizumab/iv [Intravenous Drug Administration], tislelizumab/pk [Pharmacokinetics], tislelizumab/pv [Special Situation for Pharmacovigilance], tislelizumab/tm [Unexpected Outcome of Drug Treatment], immunohistochemical test kit, VENTANA PD-L1 (SP263), maximum concentration, adult, aged, anemia/si [Side Effect], antineoplastic activity, area under the curve, article, ascites/si [Side Effect], backache/si [Side Effect], bile duct carcinoma/dt [Drug Therapy], body weight disorder/si [Side Effect], clinical outcome, cohort analysis, colitis/si [Side Effect], colorectal cancer/dt [Drug Therapy], constipation/si [Side Effect], controlled study, coughing/si [Side Effect], diarrhea/si [Side Effect], drug dosage form comparison, drug dose escalation, drug dose regimen, drug efficacy, drug half life, drug safety, drug tolerability, drug withdrawal, dysphagia/si [Side Effect], dyspnea/si [Side Effect], esophagus cancer/dt [Drug Therapy], esophagus carcinoma/dt [Drug Therapy], fatigue/si [Side Effect], female, follow up, gastrointestinal stromal tumor/dt [Drug Therapy], head and neck squamous cell carcinoma/dt [Drug Therapy], human, hyperbilirubinemia/si [Side Effect], Article

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29145
    Journal for ImmunoTherapy of Cancer
    LibKey Link

  6. 6
    مورد إلكتروني

    مصطلحات الفهرس: endometrium cancer/di [Diagnosis], endometrium cancer/dt [Drug Therapy], endometrium cancer/et [Etiology], enzyme inhibition, fatigue/si [Side Effect], female, fever/si [Side Effect], gastroesophageal reflux/si [Side Effect], glossodynia/si [Side Effect], hand foot syndrome/si [Side Effect], headache/si [Side Effect], human, hyperkeratosis/si [Side Effect], hypertension/si [Side Effect], hypomagnesemia/si [Side Effect], hypophosphatemia/si [Side Effect], hypotension/si [Side Effect], insomnia/si [Side Effect], intestine obstruction/si [Side Effect], intestine perforation/si [Side Effect], lethargy/si [Side Effect], limb pain/si [Side Effect], major clinical study, male, maximum plasma concentration, maximum tolerated dose, melanoma/di [Diagnosis], melanoma/dt [Drug Therapy], melanoma/et [Etiology], multiple cycle treatment, muscle spasm/si [Side Effect], musculoskeletal chest pain/si [Side Effect], myalgia/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non small cell lung cancer/di [Diagnosis], non small cell lung cancer/dt [Drug Therapy], non small cell lung cancer/et [Etiology], oncogene N ras, oropharynx pain/si [Side Effect], ovary cancer/di [Diagnosis], ovary cancer/dt [Drug Therapy], ovary cancer/et [Etiology], palmoplantar keratoderma/si [Side Effect], pericardial effusion/si [Side Effect], phase 1 clinical trial, photosensitivity/si [Side Effect], pleura effusion/si [Side Effect], positron emission tomography-computed tomography, priority journal, progression free survival, pruritus/si [Side Effect], QT prolongation/si [Side Effect], rash/si [Side Effect], sepsis/si [Side Effect], side effect/si [Side Effect], skin defect/si [Side Effect], skin hypertrophy/si [Side Effect], solid malignant neoplasm, thrombocytopenia/si [Side Effect], thrush/si [Side Effect], thyroid cancer/di [Diagnosis], thyroid cancer/dt [Drug Therapy], thyroid cancer/et [Etiology], thyroid papillary carcinoma/di [Diagnosis], thyroid papillary carcinoma/dt [Drug Therapy], thyroid papillary carcinoma/et [Etiology], treatment duration, upper abdominal pain/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], vomiting/si [Side Effect], xerostomia/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], B Raf kinase/ec [Endogenous Compound], K ras protein/ec [Endogenous Compound], lifirafenib/ae [Adverse Drug Reaction], lifirafenib/ct [Clinical Trial], lifirafenib/cr [Drug Concentration], lifirafenib/do [Drug Dose], lifirafenib/dt [Drug Therapy], lifirafenib/to [Drug Toxicity], lifirafenib/pd [Pharmacology], dizziness/si [Side Effect], abdominal pain/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], antineoplastic activity, arthralgia/si [Side Effect], article, backache/si [Side Effect], blood level, blood toxicity/si [Side Effect], body weight disorder/si [Side Effect], body weight loss, brain hemorrhage/si [Side Effect], cancer chemotherapy, cancer patient, cancer radiotherapy, cancer staging, cancer survival, chill/si [Side Effect], cohort analysis, colorectal cancer/di [Diagnosis], colorectal cancer/dt [Drug Therapy], colorectal cancer/et [Etiology], constipation/si [Side Effect], coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug blood level, drug dose increase, drug half life, drug safety, drug tolerability, dry skin/si [Side Effect], dysgeusia/si [Side Effect], dysphonia/si [Side Effect], dyspnea/si [Side Effect], Article

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28975
    Journal of Clinical Oncology
    LibKey Link

  7. 7
    مورد إلكتروني

    مصطلحات الفهرس: drug absorption, drug bioavailability, drug contraindication, drug efficacy, drug metabolism, drug safety, erythema annulare centrifugum/si [Side Effect], erythema multiforme/si [Side Effect], eye examination, gastrointestinal symptom/si [Side Effect], giant cell granuloma/dt [Drug Therapy], glioblastoma/dt [Drug Therapy], glucose 6 phosphate dehydrogenase deficiency, granuloma annulare/dt [Drug Therapy], heart protection, heartburn/si [Side Effect], human, hyperpigmentation/si [Side Effect], hypertransaminasemia/si [Side Effect], hypoglycemia/si [Side Effect], immunomodulation, irritability, leukopenia/si [Side Effect], lichen (disease)/dt [Drug Therapy], lichen planus/dt [Drug Therapy], lichen sclerosus et atrophicus/dt [Drug Therapy], liver toxicity/si [Side Effect], lung cancer/dt [Drug Therapy], lupus vulgaris/dt [Drug Therapy], measles like rash/si [Side Effect], melanoma/dt [Drug Therapy], mood change, morphea/dt [Drug Therapy], mucinosis/dt [Drug Therapy], multiple myeloma/dt [Drug Therapy], nausea/si [Side Effect], necrobiosis lipoidica/dt [Drug Therapy], nightmare/si [Side Effect], nonhuman, outcome assessment, pancreas cancer/dt [Drug Therapy], panniculitis/dt [Drug Therapy], patient monitoring, pharmacodynamics, photodermatosis/dt [Drug Therapy], porphyria cutanea tarda/dt [Drug Therapy], practice guideline, pregnancy, prescription, pruritus/si [Side Effect], psoriasis/si [Side Effect], rash/si [Side Effect], retina maculopathy/si [Side Effect], retinopathy/si [Side Effect], review, risk benefit analysis, risk reduction, sarcoma/dt [Drug Therapy], side effect/si [Side Effect], skin contusion/si [Side Effect], skin sarcoidosis/dt [Drug Therapy], smoking, solid malignant neoplasm/dt [Drug Therapy], Stevens Johnson syndrome/si [Side Effect], systemic lupus erythematosus/dt [Drug Therapy], systemic sclerosis/dt [Drug Therapy], toxic epidermal necrolysis/si [Side Effect], treatment response, urticaria/si [Side Effect], vasculitis/dt [Drug Therapy], visual impairment/si [Side Effect], vomiting/si [Side Effect], cyclosporine/it [Drug Interaction], digoxin/it [Drug Interaction], glucose 6 phosphate dehydrogenase/ec [Endogenous Compound], hydroxychloroquine/ae [Adverse Drug Reaction], hydroxychloroquine/it [Drug Interaction], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/pk [Pharmacokinetics], hydroxychloroquine/pd [Pharmacology], methotrexate/it [Drug Interaction], follicular mucinosis/dt [Drug Therapy], lichen planopilaris/dt [Drug Therapy], reticular erythematous mucinosis/dt [Drug Therapy], urticarial vasculitis/dt [Drug Therapy], laboratory test, abdominal distension/si [Side Effect], acute generalized exanthematous pustulosis/si [Side Effect], agranulocytosis/si [Side Effect], alopecia/si [Side Effect], alopecia areata/dt [Drug Therapy], anorexia/si [Side Effect], antineoplastic activity, antiphospholipid syndrome/dt [Drug Therapy], antithrombotic activity, aplastic anemia/si [Side Effect], blood toxicity/si [Side Effect], chronic urticaria/dt [Drug Therapy], dermatology, dermatomyositis/dt [Drug Therapy], diarrhea/si [Side Effect], DRESS syndrome/si [Side Effect], Review

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35375
    Australasian Journal of Dermatology
    LibKey Link

  8. 8
  9. 9
    مورد إلكتروني

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35830
    Medical Journal of Australia
    Click here for full text options
    LibKey Link

  10. 10
    مورد إلكتروني

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35830
    Medical Journal of Australia
    LibKey Link